RE:RE:RE:RE:RE:CYCLIC GLYCOAMINOACID DERIVATIVESOk Don/Dave/Richard/Tyler, we don't need to put people through this.
The facts are that the patent filing on Anti aging is happening in a multitude of regions and countries around the world, including the European Union which as we know is a key market.
I have checked with the company in the past, and there is an assessed high likelihood of patent being awarded and no concern moving the tech forward to market in the meantime. In fact, the current status is not an obstacle to signing a decent agreement globally or in specific regions, or even if they decided to execute an interim strategy to get it to market on their own.
The clinical results are the facts here on Anti-aging, and that is the asset that will drive valuation, along with booked revenue upon the launch of 1067. As far as I have been able to determine, the plans by AbbVie/Allergan remain unwaivered, and when the company can announce the market introduction, we will know then. Because of the R&F debacle, the share price is unfortunately severely tainted with the same assumptions, but if you look at the history of the Allergan Sirona relationship here, and dig deep, one will find that Allergan has been courting Sirona for over a decade for access to Geraldine's tech here, and that same head of cosmetics is still there and pushing hard to get this to market. Can't ask for better than that.
Saying that is at high risk at this point would be uninformed or outright irresponsible at this time in my view. Things could change, sure, but that is not what I see at present day.
Next time you want to post, think about offering something of value - this is supposed to be a community of like minded investors and we all want this one to succeed, even you.